**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 71397

**Manuscript Type:** MINIREVIEWS

**Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification**

Xu JX *et al*. Immunotherapies for G3 GEP-NETs

Jun-Xi Xu, De-Hao Wu, Li-Wei Ying, Han-Guang Hu

**Jun-Xi Xu, Han-Guang Hu,** Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang Province, China

**De-Hao Wu,** Cancer Institute, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang Province, China

**Li-Wei Ying,** Department of Orthopedic, Taizhou Hospital, Wenzhou Medical University, Linhai 317000, Zhejiang Province, China

**Author contributions:** Xu JX designed the review, drafted the manuscript, sorted and analyzed the data, and prepared the table; Wu DH and Ying LW assisted in editing the table and contributed to clinical data collection; Hu HG coordinated the design of the outline and critically revised the paper; all authors have read and approved the final manuscript.

**Corresponding author: Han-Guang Hu, PhD, Academic Fellow, Associate Chief Physician, Doctor, Professor,** Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou 310009, Zhejiang Province, China. huhanguang@zju.edu.cn

**Received:** September 8, 2021

**Revised:** October 28, 2021

**Accepted:** November 30, 2021

**Published online:** December 21, 2021

**Abstract**

According to the 2019 World Health Organization (WHO) classification, well-differentiated grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) are a new category of cancer of the digestive system. G3 GEP-NET research and treatment are not as robust as those of lower grade (G1/2) NETs and poorly differentiated neuroendocrine carcinomas (NECs). Previously, the management of high-grade NETs was mainly based on NEC therapies, as high-grade NETs were classified as NECs under the previous WHO classification. Despite this, G3 GEP-NETs are significantly less responsive to platinum-based chemotherapy regimens than NECs, due to their distinct molecular pathogenesis and course of pathological grade transition. Patients with advanced G3 GEP-NETs, who have progressed or are intolerant to chemotherapy regimens such as capecitabine plus temozolomide, have limited treatment choices. Immunotherapy has helped patients with a variety of cancers attain long-term survival through the use of immune checkpoint inhibitors (ICIs). Immunotherapies, either alone or in combination with other therapies, do not have a clear function in the treatment of G3 GEP-NETs. Currently, the majority of immunotherapy studies, both prospective and retrospective, do not reliably differentiate G3 GEP-NETs from NECs. By contrast, a significant number of studies include non-GEP neuroendocrine neoplasms (NENs). Therefore, there is an urgent need to summarize and evaluate these data to provide more effective therapeutic approaches for patients with this rare tumor. The purpose of this mini-review was to screen and summarize information on G3 GEP-NETs from all studies on NENs immunotherapy.

**Key Words:** Gastrointestinal tract; Pancreas; Immune checkpoint inhibitors; Immunotherapy; Neuroendocrine tumors; Cytotoxic T-lymphocyte-associated protein 4 antigen

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Xu JX, Wu DH, Ying LW, Hu HG. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification. *World J Gastroenterol* 2021; 27(47): 8123-8137

URL: <https://www.wjgnet.com/1007-9327/full/v27/i47/8123.htm>

DOI: https://dx.doi.org/10.3748/wjg.v27.i47.8123

**Core Tip:** Several evaluations have been published on immunotherapy for neuroendocrine neoplasms. However, this is the first review to specifically focus on the efficacy of different immunotherapy strategies such as immune checkpoint inhibitor (ICI) monotherapy, dual ICI therapy, anti-angiogenesis plus ICI, and chemotherapy combined with ICI for the treatment of advanced well-differentiated high-grade gastroenteropancreatic neuroendocrine tumors.

**INTRODUCTION**

Neuroendocrine neoplasms (NENs) are rare and indolent diseases that can manifest in any part of the body where peptidergic neurons and neuroendocrine cells are found. About 65% of neoplasms are found in the gastrointestinal (GI) tract and pancreas, making gastroenteropancreatic (GEP)-NENs the most common type of NENs[1]. Due to advancements in early-stage disease detection techniques such as endoscopy and imaging, the incidence of GEP-NENs has significantly increased to an overall incidence of 3.56 per 100000[2]. Based on the 2010 grading system, the World Health Organization (WHO) in 2019 comprehensively considered the importance of the primary site, morphological differentiation, and grading in the classification of GEP-NENs, and expanded the 2017 grading system by proposing a classification framework for all NENs[3]. One of the key updates in the 2019 classification system is that all grade 3 (G3) NENs (with Ki-67 proliferation index > 20%) are classified as either well-differentiated G3 neuroendocrine tumors (NETs) or poorly differentiated neuroendocrine carcinomas (NECs). Although G3 NETs have more inert biological behavior compared to NECs, they have a poorer prognosis compared to G1/2 NETs[4]. Compared to patients with poorly differentiated NECs, well-differentiated G3 NET patients have a considerably longer median overall survival (mOS) (41-99 mo *vs* 17 mo)[5].

G3 NENs account for 13.4% of all digestive system NENs, whereas G3 NETs account for 18%-20% of G3 GEP-NENs[6,7]. In general, although significant progress has been made in the management of GEP-NENs as a whole, the treatment of G3 GEP-NETs, a new WHO category, has not been well studied. Therefore, more tailored treatment strategies are needed for these disorders.

According to WHO 2010 classification criteria, G3 GEP-NETs were categorized as NECs. However, clinical variations between individuals with G3 GEP-NETs and NECs were discovered. For example, platinum-based chemotherapy was frequently employed for the treatment of G3 GEP-NEN patients in the past. Patients with G3 NETs or Ki-67 < 55% (mostly well-differentiated) were significantly less responsive to treatment than those with NEC or Ki-67 ≥ 55% (mostly poorly differentiated). G3 NET and NEC patients have an objective response rate (ORR) of less than 17% and 35%-70%, a median progression-free survival rate (mPFS) of 2.4-4 mo and 5.0 mo, and mOS of 17 mo and 99 mo, respectively[8-10].

Recently, the first prospective Phase II study of capecitabine with temozolomide in patients with high-grade GEP-NEN and Ki-67 index < 55% yielded results contrary to those received platinum plus etoposide. Patients with G3 NET (*n* = 23) responded better to treatment than those with NEC (*n* = 7) in both short-term [ORR 34.8% *vs* 14.3%, *P* = 0.393; disease control rate (DCR) 87.0% *vs* 42.9%, *P* = 0.033] and long-term (mPFS 9.3 mo *vs* 3.5 mo, *P* = 0.005; mOS did not reach *vs* 6.2 mo, *P* = 0.004) evaluations[11]. In addition, a retrospective study showed that the first-line fluoropyrimidine-based regimens with oxaliplatin (FOLFOX/XELOX) also achieved superior results (mPFS of 7.9 mo and mOS of 30 mo) in 34 patients with G3 GEP-NETs[12].

However, there is no established treatment for G3 GEP-NET patients who are insensitive or resistant to chemotherapy. Peptide receptor radionuclide therapy (PRRT) is a promising alternative approach to chemotherapy. In a retrospective cohort study, PRRT was delivered to G3 GEP NEN patients and their response was examined. The study found that ORR was not significantly different across well-differentiated (*n* = 60) and poorly differentiated (*n* = 62) disease subgroups (42% *vs* 43%). However, DCR, mPFS, and mOS were much longer in patients with well-differentiated tumors than those with poorly differentiated cancers (DCR 93% *vs* 68%, mPFS 19 mo *vs* 8 mo, and mOS 44 mo *vs* 19 mo)[13]. Regrettably, this new therapy is only available in a few countries. Therefore, there is an urgent need to compensate for the inadequacies of the aforementioned medications in patients with G3 GEP-NETs.

In recent years, immunotherapy has emerged as a new and intriguing approach for cancer therapy. Cancer cells have the inherent ability to express negative regulatory molecules of immune cells. The cornerstone of immunotherapy in modern oncology aims to improve the ability of the immune system to recognize and kill tumor cells[14]. Currently, this is being achieved through the use of monoclonal antibodies against immune checkpoints such as programmed death-ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Immune checkpoint inhibitors (ICIs), which sit at the forefront of cancer immunotherapy, have revolutionized the management of a variety of solid malignancies. In relation to NENs, immunotherapy has been mainly used to treat lung and skin tumors such as Merkel cell carcinoma, malignant melanoma, and small cell lung cancer (SCLC)[15]. Although an increasing number of clinical trials and retrospective studies are being conducted to investigate the efficacy of ICIs on NENs of the digestive tract, the role of immunotherapy approaches in well-differentiated G3 NETs has not been sufficiently studied.

In this minireview, we briefly describe the overall pathological changes of G3 GEP-NETs and analyze in detail the immunotherapy experience with well-differentiated G3 GEP-NETs from complex investigations.

**ROLE OF IMMUNOTHERAPY IN G3 GEP-NETS**

A recent systematic review and meta-analysis of 636 NEN patients treated with ICIs reported an ORR of 10% [95% confidence interval (CI): 6%-15%, *I2* = 67%, *P* < 0.1], a total DCR of 42%, a mPFS of 4.1 mo (95%CI: 2.6-5.4; *I2* = 96%, *P* < 0.1), and a mOS of 11 mo (95%CI: 4.8-21.1; *I2* = 98%, *P* < 0.1)[16]. This demonstrated the overall effectiveness of ICIs in treating NEN patients. Among the NEN study subjects, about 37% were patients with NENs originating from the lung or other unknown sites and only 13.4% were patients who had G3 NETs. However, the study did not include a separate subgroup of G3 GEP-NET patients in its analysis. Previous studies have shown that G3 NETs can share a common pathogenesis with G1-2 NETs[17]. Moreover, more than half of G1-2 pancreatic NETs (pNETs) developed progressively into G3 pNENs over time[18]. Some researchers have even speculated that high-grade pNET may develop from the initial low- and medium-grade NET, while pNEC may develop from pancreatic ductal adenocarcinoma[19,20]. Therefore, the response of lower grade NETs to immunotherapy may have some implications for the treatment of G3 NETs. Other aspects that may influence the immunotherapy choices for G3 GEP-NETs include the presence of predictive biomarkers for ICIs in tumors with high proliferative activity as well as changes in pathological grade over time.

Table 1 summarizes the clinical trials of immunotherapy in GEP-NENs. Below, we presented data from clinical trials and retrospective studies that may have included cases with G3 GEP-NETs. Additionally, we analyzed the data to determine the efficacy of different immunotherapy strategies such as PD-1/PD-L1 inhibitors as a monotherapy or in combination with CTLA-4 inhibitors, anti-angiogenesis, and chemotherapy in the management of these rare diseases.

***ICIs monotherapy***

Pembrolizumab is the most extensively investigated immunotherapy for NENs. For example, phase Ib (KEYNOTE-28) and phase II (KEYNOTE-158) clinical trials were conducted to evaluate pembrolizumab monotherapy in patients with moderately or well-differentiated NETs. In these two studies, no data on tumor grade and Ki-67 index were collected. The results of the KEYNOTE-28 trial showed an ORR of 6.3% in pNETs[21]. The preliminary results of the KEYNOTE-158 study showed that mixed NETs had an ORR of 3.7% and that all reactive tumors were PD-L1-negative[22]. In addition, two prospective randomized phase II trials were performed to evaluate pembrolizumab in 19 patients with NECs and 9 with G3 NETs. There were no responses to pembrolizumab in patients with GI tract or pancreatic diseases[23]. In a trial of 14 patients with extrapulmonary poorly differentiated NECs, only 1 patient achieved complete remission (CR) (ORR 7%) following pembrolizumab monotherapy[24]. From the abovementioned studies, it can be concluded that pembrolizumab alone has a very limited curative effect on the GEP-NENs independent of their proliferative activity or differentiation. The only clinical trial (NCT02955069) of spartalizumab, a PD-1 inhibitor, for the treatment of NENs excluded patients with G3 NETs and achieved low efficacy comparable to pembrolizumab[25]. Avelumab is the only PD-L1 inhibitor used as a single drug in prospective clinical trials for GEP-NENs. Four phase II clinical trials (NCT03352934[26], NCT03278405[27], NCT03278379[28], and NCT03147404) were conducted to evaluate avelumab in patients with G2/3 NETs or NEC. The trials revealed that none of the patients achieved an objective response to avelumab treatment. In addition, none of the 3 G3 NET patients analyzed in a retrospective study from the Mayo Clinic exhibited an objective response to ICI (pembrolizumab, nivolumab, or atezolizumab) monotherapy[29].

Toripalimab (JS001) is a humanized PD-1 IgG4 monoclonal antibody developed in China. In a phase Ib study (NCT03167853) involving 40 NEN patients with Ki-67 ≥ 10%, toripalimab showed moderate efficacy in both well-differentiated NETs and poorly differentiated NECs (ORR: 25.0% *vs* 18.7% per RECIST 1.1, 25.0% *vs* 25.0% per irRECIST)[30]. This suggests that toripalimab may be the most effective ICI monotherapy currently available for NENs, including G3 NETs. The study also found that patients with PD-L1 expression ≥ 10% or with high tumor mutational burden (TMB) had a better ORR than patients with PD-L1 < 10% (50.0% *vs* 10.7%, *P* = 0.019) or with low TMB (75.0% *vs* 16.1%, *P* = 0.03)[30].

***Anti-angiogenesis combined with ICIs***

NENs from different tissues are highly vascularized and express a variety of growth factors including vascular endothelial growth factor (VEGF), platelet-derived growth factor, basic fibroblast growth factor, insulin-like growth factor 1, and transforming growth factor-α/β[31]. The high exposure and activation of VEGFs prevent the immune system from recognizing and killing cancer cells killing tumor cells[32,33].

The hallmark of angiogenesis is the uncontrolled development of new vessels from adjacent normal tissues. This results in a network of immature microvessels characterized by structural and functional abnormalities. The normalizing vascular structure can be achieved with antiangiogenic drugs, including large-molecule monoclonal antibodies and small-molecule tyrosine kinase inhibitors. This results in the activation of adhesion molecules and chemokines that recruit and attract cytotoxic T cells and reduce the entry of regulatory T cells. Moreover, it contributes to immune cell mobilization[34,35].

Surufatinib is a small molecule inhibitor that mainly targets VEGF-1, 2, 3 (VEGFR-1, 2, 3), fibroblast growth factor receptor-1, and colony-stimulating factor-1 receptor (CSF-1R). Blocking of CSF-1R can reduce the polarization of tumor-associated macrophages to the M2 type that participates in immunosuppression and promotes tumor growth[36,37]. Two randomized, double-blind phase III clinical trials (SANET-ep and SANET-p) were carried out to evaluate surufatinib *vs* placebo in Chinese patients with G1-2 NETs. The results indicated that surufatinib can significantly prolong PFS in patients with advanced pancreatic and non-pancreatic G1-2 NETs compared with placebo[37,38]. At present, a phase I trial and a phase II trial of surufatinib combined with toripalimab on patients with NENs are underway. In a phase I clinical trial (NCT03879057), as of 2020-1-20, PR occurred in G1/2 NET (2/4) and NECs (2/11) patients; however, none of the 4 patients with G3 NETs achieved disease remission[39], which may be attributed to the small sample size of patients with G3NETs. In the phase II trial (NCT04169672), 20 evaluable patients with NECs and refractory to first-line chemotherapy achieved a moderate ORR of 20% and a DCR of 70%[40]. However, no data for well-differentiated NETs have been reported. In addition, two prospective studies involving G3 GEP-NETs patients are currently recruiting. In one of the trials, the intervention is avelumab plus regorafenib, while in the other study, the intervention is pembrolizumab plus lenvatinib. The studies are expected to be completed in May 2022 and December 2023, respectively. The combination treatment of atezolizumab and bevacizumab in a phase II basket trial (NCT03074513) showed moderate clinical activity and good tolerance in G1-2 pNETs and extra-pNETs (ORR 20% and 15%, respectively) patients with prior therapy[41]. However, the data of G3 NETs have not been reported either.

Given the favorable preliminary results in patients with G1-2 NETs and NECs, researchers might be optimistic about the combination therapy’s effectiveness in patients with G3 NETs.

***Dual ICI therapy***

The United States Food and Drug Administration has approved ipilimumab (anti-CTLA-4) combined with nivolumab (anti-PD-1) (N+I) for melanoma, metastatic renal cell carcinoma, advanced hepatocellular carcinoma, and previously untreated unresectable malignant pleural mesothelioma[42-44]. Response rates with this combination are higher compared to single-agent anti-PD-1 therapy. For NENs, a phase II clinical trial (CA209-538) of N+I demonstrated a moderate overall ORR of 24%, especially in patients with G3 NENs and atypical bronchial carcinoid[45]. In the study, 7 patients with pNENs and 3 with GI-NENs achieved an ORR of 43% and 33.3%, respectively. All responders had a high-grade disease. It is worth noting that 2 of the 3 patients with G3 pNET achieved an objective response. This result is a breakthrough in the application of ICIs in the treatment of G3 GEP-NET. Currently, a phase II study (NCT04969887) on evaluation of N+I in patients with immunotherapy-sensitive cancers including NECs and G3 NETs from CA209-538 has been registered and is expected to be completed in October 2024.

Another phase II basket study of N+I for the treatment of rare tumors called SWOG DART (NCT02834013) was recently reported. In one cohort, 32 patients with epNENs (excluding SCLC, about 50% have GI-NENs) had a significantly higher response rate for high-grade neoplasms than for middle/low-grade neoplasms (ORR 44% *vs* 0%, *P* = 0.004) with no difference in overall ORR between the different primary origins[15]. Based on the results of the cohort, a second and dedicated cohort of 19 individuals with G3 NENs was explored[46]. Although all patients were microsatellite-stable, the results of the cohort revealed a moderate ORR of 26%. Unfortunately, none of the above cohorts performed an analysis of G3 NENs according to differentiation. A similar dilemma existed in a retrospective study at Moffet Cancer Center and the Mayo Clinic, where G3 NEN patients achieved an ORR of 14.75%. Therefore, determining the efficacy of N+I in the treatment of well-differentiated G3 GEP-NETs is challenging.

Durvalumab (anti-PD-L1) in combination with tremelimumab (anti-CTLA-4) (D+T) is another dual ICI therapy that has been studied for advanced NENs of GEP or lung origin. The initial results of DUNE, a prospective phase II multi-cohort study, were presented at the 2020 ESMO Annual meeting[47]. Cohort 4 consisting of 33 G3 GEP-NENs achieved an ORR of 9.1%, and the clinical benefit rate of 36.1% at 9-mo paved the way for a phase III clinical trial of D+T. Regrettably, comparable to N+I, no independent examination of patients with well-differentiated tumors was conducted, although the efficacy of G3 was higher than that of G1-2.

The above results suggest that dual ICIs have moderate overall efficacy in patients with advanced G3 GEP-NENs. Comparatively, the N+I regimen appears to have a greater response rate than D+T. The success of these therapies, however, must be demonstrated in a large number of patients with well-differentiated G3 GEP-NETs.

***Chemotherapy combined with ICI***

Current research on chemotherapy combined with ICIs, in the field of GEP-NENs, has a small sample size and the majority of them include previously treated NECs. The ORRs vary from 9% for pembrolizumab plus dealers’ choice chemotherapy to 36% for nivolumab plus temozolomide[29,48,49]. Since most NEC patients are sensitive to chemotherapy, it is necessary to compare the above results with the data of chemotherapy alone as a second- or later-line treatment option. This comparison will establish whether NEC patients can significantly benefit from the above combination therapy. As previously described, G3 NETs are insensitive to platinum-based chemotherapy. Unfortunately, G3 GEP-NET, as a well-differentiated tumor with high proliferative activity, has not been specifically included in any prospective clinical trials for chemotherapy combined with ICI.

***Other immunotherapies***

Immunotherapies currently being investigated in prospective clinical trials related to G3 GEP-NET include classic PD-1 inhibitors combined with other therapies such as LAG525 (LAG-3 inhibitor), 177Lu-DOTATATE (PRRT), and liver-directed therapies (Transarterial Embolization or 90Yttrium Microsphere Radioembolization). In addition, the immune tumor vaccines Survivin Long Peptide Vaccine (SurVaxM) and Dendritic Cells Loaded with Autologous Tumor Homogenate (DC vaccine) have entered phase I and phase II clinical trials, respectively. Both vaccines are currently at the subject recruitment stage.

***Predictive biomarkers for immunotherapies***

The potential of a given patient with G3 GEP-NET to respond to immunotherapies is still largely unknown. NETs can be considered as immunologically “cold” due to their lack of immunoactive cellular components, low tumor antigens, *etc*.[50,51].

Immunohistochemical assessment of PD-L1 expression and its role in predicting response to ICIs is an incredibly hot topic. However, in the KEYNOTE-28 study, pNETs with positive PD-L1 expression achieved a low ORR of 6.3%[21]. In the KEYNOTE-158 study, all 4 GEP-NET patients who achieved PR had negative PD-L1 expression[22]. Besides, in a joint analysis of two prospective, non-randomized trials, no difference in DCR, PFS, or OS was observed between the PD-L1-negative and PD-L1-positive groups with G3 NENs[23]. In contrast, in the phase Ib trial of toripalimab in the treatment of patients with NENs (Ki-67 ≥ 10%) described above, patients with PD-L1 expression ≥ 10% had better ORR than those with PD-L1 < 10% (50.0% *vs* 10.7%, *P* = 0.019)[30]. Therefore, it appears that considering merely the negative or positive expression of PD-L1 is insufficient for identifying GEP-NET patients who may benefit from ICIs and that quantifying PD-L1 expression appears to be more significant. Furthermore, only 10% of tumors expressed PD-L1 in a large cohort of 136 patients with G3 GEP-NENs and those tumoral cells with positive PD-L1 were all in poorly differentiated cases[52]. Therefore, it is necessary to combine PD-L1 with other predictive biomarkers to better predict the population that may benefit from immunotherapy.

For other biomarkers, both high TMB (TMB-H) and microsatellite instability-high (MSI-H)/deficient mismatch repair protein (dMMR) are independent adverse prognostic factors for NENs[53] and also have an important predictive value. Wang *et al*[54] reported that 50% of the 18 Chinese patients with NETs had TMB-H. In a NET cohort analyzed by Patel *et al*[15], found no difference in the PD-L1 positivity rate between G3 and G1/G2 tumors, while the TMB-H rate was significantly higher in G3 NENs independent of tumor origin. Large samples of clinical and genomic data demonstrated that TMB-H was associated with increased survival in patients treated with ICI across various cancer types[55]. Duan *et al*[56] discovered that half of pNEN patients had decreased expression of MMR, another important biomarker. Venizelos *et al*[57] recently reported that MSI occurred in only 5.3% (8/152) of GEP-NEC patients and 3.4% (1/29) of G3 GEP-NET patients.

Pre-treatment assessment of one or more of these biomarkers provides a new perspective for screening good responders to immunotherapy.

**CONCLUSION**

In this minireview, data from prospective clinical trials and retrospective studies on the role of immunotherapies on G3 GEP-NET has been screened and reviewed. For ICI monotherapy, the efficacy of pembrolizumab, spartalizumab, and avelumab on G3 GEP-NETs is very limited. Only toripalimab has shown a moderate clinical activity on NENs with Ki-67 ≥ 10%, PD-L1 expression ≥ 10%, or high TMB. In addition, the ORR of well-differentiated tumors treated with toripalimab was slightly better than that of poorly differentiated cancers. Toripalimab and surufatinib therapy did not cause disease remission in 4 patients with G3 NETs. However, the treatment did not prevent remission in NEC and G1-2 NETs. Therefore, these regimens could potentially be effective in the treatment of G3 GEP-NETs if a large number of subjects are included. In other studies, the N+I therapy achieved PD in 2 of 3 patients with G3 NET as well as moderate efficacy in high-grade NENs. These results suggest that N+I may represent an extremely promising treatment option for G3 NET.

At present, all clinical trials investigating G3 GEP-NET are either phase I or phase II studies with small sample sizes. In this study, several challenges were encountered when collecting and evaluating data on the efficacy of immunotherapies for G3 GEP-NETs. According to the 2010 WHO classification, the inclusion of high-grade NETs in studies of NECs, the lack of Ki-67 index data in well-differentiated tumors, and the inclusion of tumors derived from lung, esophageal or unknown tissue all contribute to significant heterogeneity in reported results. Additionally, the review mainly focuses on the ORR to evaluate the potential role of immunotherapies in the treatment of G3 NETs. This is because the majority of prospective studies are ongoing and the survival data are in their infancy. Therefore, it is necessary to conduct prospective clinical trials with a large sample size of pathologically confirmed G3 GEP-NETs to evaluate the efficacy of the above immunotherapies. Besides, referencing data from important biomarkers facilitates the screening of patients who may benefit.

**ACKNOWLEDGEMENTS**

The authors express their gratitude to the scholars who have conducted prospective and retrospective studies on immunotherapies in the treatment of NENs.

**REFERENCES**

1 **Oronsky B**, Ma PC, Morgensztern D, Carter CA. Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. *Neoplasia* 2017; **19**: 991-1002 [PMID: 29091800 DOI: 10.1016/j.neo.2017.09.002]

2 **Dasari A**, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. *JAMA Oncol* 2017; **3**: 1335-1342 [PMID: 28448665 DOI: 10.1001/jamaoncol.2017.0589]

3 **Rindi G**, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, Busam KJ, de Krijger RR, Dietel M, El-Naggar AK, Fernandez-Cuesta L, Klöppel G, McCluggage WG, Moch H, Ohgaki H, Rakha EA, Reed NS, Rous BA, Sasano H, Scarpa A, Scoazec JY, Travis WD, Tallini G, Trouillas J, van Krieken JH, Cree IA. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. *Mod Pathol* 2018; **31**: 1770-1786 [PMID: 30140036 DOI: 10.1038/s41379-018-0110-y]

4 **Alevroudis E**, Spei ME, Chatziioannou SN, Tsoli M, Wallin G, Kaltsas G, Daskalakis K. Clinical Utility of 18F-FDG PET in Neuroendocrine Tumors Prior to Peptide Receptor Radionuclide Therapy: A Systematic Review and Meta-Analysis. *Cancers (Basel)* 2021; **13** [PMID: 33920195 DOI: 10.3390/cancers13081813]

5 **Shah MH**, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, Chan J, Das S, Dickson PV, Fanta P, Giordano T, Halfdanarson TR, Halperin D, He J, Heaney A, Heslin MJ, Kandeel F, Kardan A, Khan SA, Kuvshinoff BW, Lieu C, Miller K, Pillarisetty VG, Reidy D, Salgado SA, Shaheen S, Soares HP, Soulen MC, Strosberg JR, Sussman CR, Trikalinos NA, Uboha NA, Vijayvergia N, Wong T, Lynn B, Hochstetler C. Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2021; **19**: 839-868 [PMID: 34340212 DOI: 10.6004/jnccn.2021.0032]

6 **Scoazec JY**, Couvelard A, Monges G, Guyétant S, Bisot-Locard S, Parot X, Lepage C; PRONET Study Group. Professional Practices and Diagnostic Issues in Neuroendocrine Tumour Pathology: Results of a Prospective One-Year Survey among French Pathologists (the PRONET Study). *Neuroendocrinology* 2017; **105**: 67-76 [PMID: 27442514 DOI: 10.1159/000448431]

7 **Yao JC**, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. *J Clin Oncol* 2008; **26**: 3063-3072 [PMID: 18565894 DOI: 10.1200/JCO.2007.15.4377]

8 **Mollazadegan K**, Welin S, Crona J. Systemic Treatment of Gastroenteropancreatic Neuroendocrine Carcinoma. *Curr Treat Options Oncol* 2021; **22**: 68 [PMID: 34110508 DOI: 10.1007/s11864-021-00866-9]

9 **Sorbye H**, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. *Ann Oncol* 2013; **24**: 152-160 [PMID: 22967994 DOI: 10.1093/annonc/mds276]

10 **Heetfeld M**, Chougnet CN, Olsen IH, Rinke A, Borbath I, Crespo G, Barriuso J, Pavel M, O'Toole D, Walter T; other Knowledge Network members. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. *Endocr Relat Cancer* 2015; **22**: 657-664 [PMID: 26113608 DOI: 10.1530/ERC-15-0119]

11 **Jeong H**, Shin J, Jeong JH, Kim KP, Hong SM, Kim YI, Ryu JS, Ryoo BY, Yoo C. Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study. *ESMO Open* 2021; **6**: 100119 [PMID: 33901869 DOI: 10.1016/j.esmoop.2021.100119]

12 **Lamberti G**, Pusceddu S, Ibrahim T, Bongiovanni A, Berardi R, Torniai M, Prinzi N, Manuzzi L, Campana D. First-line fluoropyrimidine and oxaliplatin chemotherapy in gastroentero-pancreatic grade 3 well-differentiated neuroendocrine tumours (NET G3). Proceedings of the Annals of Oncology, 2020. Elsevier: Amsterdam, Netherlands: S776-S776

13 **Carlsen EA**, Fazio N, Granberg D, Grozinsky-Glasberg S, Ahmadzadehfar H, Grana CM, Zandee WT, Cwikla J, Walter MA, Oturai PS, Rinke A, Weaver A, Frilling A, Gritti S, Arveschoug AK, Meirovitz A, Knigge U, Sorbye H. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. *Endocr Relat Cancer* 2019; **26**: 227-239 [PMID: 30540557 DOI: 10.1530/ERC-18-0424]

14 **Clemente O**, Ottaiano A, Di Lorenzo G, Bracigliano A, Lamia S, Cannella L, Pizzolorusso A, Di Marzo M, Santorsola M, De Chiara A, Fazioli F, Tafuto S. Is immunotherapy in the future of therapeutic management of sarcomas? *J Transl Med* 2021; **19**: 173 [PMID: 33902630 DOI: 10.1186/s12967-021-02829-y]

15 **Patel SP**, Othus M, Chae YK, Giles FJ, Hansel DE, Singh PP, Fontaine A, Shah MH, Kasi A, Baghdadi TA, Matrana M, Gatalica Z, Korn WM, Hayward J, McLeod C, Chen HX, Sharon E, Mayerson E, Ryan CW, Plets M, Blanke CD, Kurzrock R. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. *Clin Cancer Res* 2020; **26**: 2290-2296 [PMID: 31969335 DOI: 10.1158/1078-0432.CCR-19-3356]

16 **Bongiovanni A**, Maiorano BA, Azzali I, Liverani C, Bocchini M, Fausti V, Di Menna G, Grassi I, Sansovini M, Riva N, Ibrahim T. Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis. *Pharmaceuticals (Basel)* 2021; **14** [PMID: 34067837 DOI: 10.3390/ph14050476]

17 **Pellat A**, Cottereau AS, Palmieri LJ, Soyer P, Marchese U, Brezault C, Coriat R. Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions. *Cancers (Basel)* 2021; **13** [PMID: 34070035 DOI: 10.3390/cancers13102448]

18 **Botling J**, Lamarca A, Bajic D, Norlén O, Lönngren V, Kjaer J, Eriksson B, Welin S, Hellman P, Rindi G, Skogseid B, Crona J. High-Grade Progression Confers Poor Survival in Pancreatic Neuroendocrine Tumors. *Neuroendocrinology* 2020; **110**: 891-898 [PMID: 31658459 DOI: 10.1159/000504392]

19 **Sorbye H**, Baudin E, Perren A. The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond. *Endocrinol Metab Clin North Am* 2018; **47**: 683-698 [PMID: 30098724 DOI: 10.1016/j.ecl.2018.05.001]

20 **Tang LH**, Untch BR, Reidy DL, O'Reilly E, Dhall D, Jih L, Basturk O, Allen PJ, Klimstra DS. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas. *Clin Cancer Res* 2016; **22**: 1011-1017 [PMID: 26482044 DOI: 10.1158/1078-0432.CCR-15-0548]

21 **Mehnert JM**, Bergsland E, O'Neil BH, Santoro A, Schellens JHM, Cohen RB, Doi T, Ott PA, Pishvaian MJ, Puzanov I, Aung KL, Hsu C, Le Tourneau C, Hollebecque A, Élez E, Tamura K, Gould M, Yang P, Stein K, Piha-Paul SA. Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. *Cancer* 2020; **126**: 3021-3030 [PMID: 32320048 DOI: 10.1002/cncr.32883]

22 **Strosberg J**, Mizuno N, Doi T, Grande E, Delord JP, Shapira-Frommer R, Bergsland E, Shah M, Fakih M, Takahashi S, Piha-Paul SA, O'Neil B, Thomas S, Lolkema MP, Chen M, Ibrahim N, Norwood K, Hadoux J. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. *Clin Cancer Res* 2020; **26**: 2124-2130 [PMID: 31980466 DOI: 10.1158/1078-0432.CCR-19-3014]

23 **Vijayvergia N**, Dasari A, Deng M, Litwin S, Al-Toubah T, Alpaugh RK, Dotan E, Hall MJ, Ross NM, Runyen MM, Denlinger CS, Halperin DM, Cohen SJ, Engstrom PF, Strosberg JR. Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials. *Br J Cancer* 2020; **122**: 1309-1314 [PMID: 32152503 DOI: 10.1038/s41416-020-0775-0]

24 **Mulvey C**, Raj NP, Chan JA, Aggarwal RR, Cinar P, Hope TA, Kolli K, Zhang L, Calabrese S, Grabowsky JA, Modarresi L, Kelly V, Stonely D, Munster PN, Reidy DL, Fong L, Bergsland EK. Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part A (pembrolizumab alone). *J Clin Oncol* 2019; **37**: 363 [DOI: 10.1200/JCO.2019.37.4\_suppl.363]

25 **Yao JC**, Strosberg J, Fazio N, Pavel ME, Bergsland E, Ruszniewski P, Halperin DM, Li D, Tafuto S, Raj N, Campana D, Hijioka S, Raderer M, Guimbaud R, Gajate P, Pusceddu S, Reising A, Degtyarev E, Shilkrut M, Eddy S, Singh S. Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms. *Endocr Relat Cancer* 2021 [PMID: 33480358 DOI: 10.1530/ERC-20-0382]

26 **Fottner C**, Apostolidis L, Ferrata M, Krug S, Michl P, Schad A, Roth W, Jaeger D, Galle PR, Weber MM. A phase II, open label, multicenter trial of avelumab in patients with advanced, metastatic high-grade neuroendocrine carcinomas NEC G3 (WHO 2010) progressive after first-line chemotherapy (AVENEC). *J Clin Oncol* 2019; **37**: 4103 [DOI: 10.1200/JCO.2019.37.15\_suppl.4103]

27 **Kaufman HL**, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. *Lancet Oncol* 2016; **17**: 1374-1385 [PMID: 27592805 DOI: 10.1016/S1470-2045(16)30364-3]

28 Abstracts Presented at the 13th Annual Multidisciplinary Neuroendocrine Tumor Medical Virtual Symposium of the North American Neuroendocrine Tumor Society, October 2-3, 2020. *Pancreas* 2021; **50**: 441-467 [PMID: 33835977 DOI: 10.1097/MPA.0000000000001763]

29 **Gile JJ**, Liu AJ, McGarrah PW, Eiring RA, Hobday TJ, Starr JS, Sonbol MB, Halfdanarson TR. Efficacy of Checkpoint Inhibitors in Neuroendocrine Neoplasms: Mayo Clinic Experience. *Pancreas* 2021; **50**: 500-505 [PMID: 33939660 DOI: 10.1097/MPA.0000000000001794]

30 **Lu M**, Zhang P, Zhang Y, Li Z, Gong J, Li J, Li J, Li Y, Zhang X, Lu Z, Wang X, Zhou J, Peng Z, Wang W, Feng H, Wu H, Yao S, Shen L. Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial. *Clin Cancer Res* 2020; **26**: 2337-2345 [PMID: 32086343 DOI: 10.1158/1078-0432.CCR-19-4000]

31 **Cives M**, Pelle' E, Quaresmini D, Rizzo FM, Tucci M, Silvestris F. The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications. *Neuroendocrinology* 2019; **109**: 83-99 [PMID: 30699437 DOI: 10.1159/000497355]

32 **Griffioen AW**, Damen CA, Blijham GH, Groenewegen G. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. *Blood* 1996; **88**: 667-673 [PMID: 8695814 DOI: 10.1182/blood.V88.2.667.bloodjournal882667]

33 **Manegold C**, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Yang JC, Zhou C, Vokes E. The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. *J Thorac Oncol* 2017; **12**: 194-207 [PMID: 27729297 DOI: 10.1016/j.jtho.2016.10.003]

34 **Shrimali RK**, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. *Cancer Res* 2010; **70**: 6171-6180 [PMID: 20631075 DOI: 10.1158/0008-5472.CAN-10-0153]

35 **Jimenez C**, Fazeli S, Román-Gonzalez A. Antiangiogenic therapies for pheochromocytoma and paraganglioma. *Endocr Relat Cancer* 2020; **27**: R239-R254 [PMID: 32369773 DOI: 10.1530/ERC-20-0043]

36 **Lin Y**, Xu J, Lan H. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. *J Hematol Oncol* 2019; **12**: 76 [PMID: 31300030 DOI: 10.1186/s13045-019-0760-3]

37 **Xu J**, Shen L, Bai C, Wang W, Li J, Yu X, Li Z, Li E, Yuan X, Chi Y, Yin Y, Lou W, Xu N, Bai Y, Zhang T, Xiu D, Wang X, Yuan Y, Chen J, Qin S, Jia R, Lu M, Cheng Y, Zhou Z, Li J, He J, Su W. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. *Lancet Oncol* 2020; **21**: 1489-1499 [PMID: 32966810 DOI: 10.1016/S1470-2045(20)30493-9]

38 **Xu J**, Shen L, Zhou Z, Li J, Bai C, Chi Y, Li Z, Xu N, Li E, Liu T, Bai Y, Yuan Y, Li X, Wang X, Chen J, Ying J, Yu X, Qin S, Yuan X, Zhang T, Deng Y, Xiu D, Cheng Y, Tao M, Jia R, Wang W, Li J, Fan S, Peng M, Su W. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. *Lancet Oncol* 2020; **21**: 1500-1512 [PMID: 32966811 DOI: 10.1016/S1470-2045(20)30496-4]

39 **Cao Y**, Lu M, Sun Y, Gong J, Li J, Lu Z, Li J, Zhang X, Li Y, Peng Z, Zhou J, Wang X, Shen L. Surufatinib Plus Toripalimab in Patients with Advanced Solid Tumors: A Single-Arm, Open-Label, Phase 1 Trial. 2020 Preprint. Available from: Research Square [DOI: 10.21203/rs.3.rs-125321/v1]

40 **Shen L**, Yu X, Lu M, Zhang X, Cheng Y, Zhang Y, Li Z, Xu J, Weng D, Wu C, Ma Y, Cheng K, WANG W, Gao H, Li Y, Zhou J, Shi H, Tan P, Su W. Surufatinib in combination with toripalimab in patients with advanced neuroendocrine carcinoma: Results from a multicenter, open-label, single-arm, phase II trial. *J Clin Oncol* 2021; **39**: e16199 [DOI: 10.1200/JCO.2021.39.15\_suppl.e16199]

41 **Halperin DM**, Liu S, Dasari A, Fogelman DR, Bhosale P, Mahvash A, Dervin S, Estrella J, Cortazar P, Maru DM, Mckenna EF, Wistuba II, Schulze K, Futreal PA, Darbonne WC, Yun C, Hwu P, Yao JC. A phase II trial of atezolizumab and bevacizumab in patients with advanced, progressive neuroendocrine tumors (NETs). *J Clin Oncol* 2020; **38**: 619 [DOI: 10.1200/JCO.2020.38.4\_suppl.619]

42 **Wright K**. FDA Approves Nivolumab Plus Ipilimumab for the Treatment of Advanced HCC. *Oncology (Williston Park)* 2020; **34** [PMID: 32293694]

43 **Campbell MT**, Xie W, Shah AY, Habra MA, Jimenez C, Venkatesan AM, Bubley G, McKay RR, Choueiri TK, McGregor BA, Killbridge KL, Mortazavi A, Bilen MA. Initial results of a phase II study of nivolumab and ipilimumab in metastatic adrenal tumours. *Ann Oncol* 2019; **30** [DOI: 10.1093/annonc/mdz249.082]

44 **Wright K**. FDA Approves Nivolumab Plus Ipilimumab for Previously Untreated Unresectable Malignant Pleural Mesothelioma. *Oncology (Williston Park)* 2020; **34**: 502-503 [PMID: 33206991 DOI: 10.46883/ONC.2020.3411.0502]

45 **Klein O**, Kee D, Markman B, Michael M, Underhill C, Carlino MS, Jackett L, Lum C, Scott C, Nagrial A, Behren A, So JY, Palmer J, Cebon J. Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers. *Clin Cancer Res* 2020; **26**: 4454-4459 [PMID: 32532787 DOI: 10.1158/1078-0432.CCR-20-0621]

46 **Patel SP**, Mayerson E, Chae YK, Strosberg J, Wang J, Konda B, Hayward J, McLeod CM, Chen HX, Sharon E, Othus M, Ryan CW, Plets M, Blanke CD, Kurzrock R. A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort. *Cancer* 2021; **127**: 3194-3201 [PMID: 33882143 DOI: 10.1002/cncr.33591]

47 **Capdevila J**, Teule A, López C, García-Carbonero R, Benavent M, Custodio A, Cubillo A, Alonso V, Gordoa TA, Carmona-Bayonas A, Crespo G, Blanco-Codesido M, Jimenez-Fonseca P, Viúdez A, La Casta Muñoa A, Sevilla I, Llanos M, Segura A, Hernando-Cubero J, Manzano JL. A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601). *Ann Oncol* 2020; **31**: S770-S771 [DOI: 10.1016/j.annonc.2020.08.1370]

48 **Chan JA**, Raj NP, Aggarwal RR, Calabrese S, DeMore A, Dhawan MS, Fattah D, Fong L, Grabowsky J, Hope TA, Kolli KP, Munster PN, Perez K, Reidy DL, Fedak SV, Zhang L, Bergsland EK. Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part B (pembrolizumab + chemotherapy). *J Clin Oncol* 2021; **39**: 4148 [DOI: 10.1200/JCO.2021.39.15\_suppl.4148]

49 **Owen DH**, Wei L, Goyal A, Zhou Y, Suffren SA, Jacob R, Pilcher C, Otterson GA, Verschraegen CF, Shah MH, Konda B. CLO20-054: A Phase 2 Trial of Nivolumab and Temozolomide in Advanced Neuroendocrine Tumors (NETs): Interim Efficacy Analysis. *JNCCN* 2020; **18**: CLO020-054 [DOI: 10.6004/jnccn.2019.7460]

50 **Takahashi D**, Kojima M, Suzuki T, Sugimoto M, Kobayashi S, Takahashi S, Konishi M, Gotohda N, Ikeda M, Nakatsura T, Ochiai A, Nagino M. Profiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 Classification. *Sci Rep* 2018; **8**: 13166 [PMID: 30177687 DOI: 10.1038/s41598-018-31383-9]

51 **de Hosson LD**, Takkenkamp TJ, Kats-Ugurlu G, Bouma G, Bulthuis M, de Vries EGE, van Faassen M, Kema IP, Walenkamp AME. Neuroendocrine tumours and their microenvironment. *Cancer Immunol Immunother* 2020; **69**: 1449-1459 [PMID: 32270230 DOI: 10.1007/s00262-020-02556-1]

52 **Ali AS**, Langer SW, Federspiel B, Hjortland GO, Grønbæk H, Ladekarl M, Welin S, Weber Vestermark L, Arola J, Osterlund P, Knigge U, Sørbye H, Micke P, Grimelius L, Grönberg M, Tiensuu Janson E. PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3. *PLoS One* 2020; **15**: e0243900 [PMID: 33315908 DOI: 10.1371/journal.pone.0243900]

53 **La Salvia A**, Barroso G, Espinosa Olarte P, Anton Pascual B, Modrego Sanchez A, Riesco-Martinez M, Garcia-Carbonero R. High TMB and MSI-high as independent predictors of survival in NENs. Proceedings of the J Neuroendocrinol, 2021. Wiley, Hoboken: NJ, USA: 108

54 **Wang S**, Fang Y, Jiang N, Xing S, Li Q, Chen R, Yi X, Zhang Z, Li N. Comprehensive Genomic Profiling of Rare Tumors in China: Routes to Immunotherapy. *Front Immunol* 2021; **12**: 631483 [PMID: 33732253 DOI: 10.3389/fimmu.2021.631483]

55 **Samstein RM**, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D'Angelo SP, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. *Nat Genet* 2019; **51**: 202-206 [PMID: 30643254 DOI: 10.1038/s41588-018-0312-8]

56 **Duan X**, Hao S, Zhao M, Mi L, Shi J, Li N, Yin X, Han X, Han G, Wang J. Mismatch repair protein and PD-1/PD-L1 expression in pancreatic neuroendocrine neoplasm. Proceedings of the J Neuroendocrinol, 2021. 2021. Wiley, Hoboken: NJ, USA: 106

57 **Venizelos A**, Elvebakken H, Perren A, Nikolaienko O, Deng W, Lothe IMB, Couvelard A, Hjortland GO, Sundlöv A, Svensson JB, Garresori H, Kersten C, Hofsli E, Detlefsen S, Krogh M, Sorbye H, Knappskog S. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. *Endocr Relat Cancer* 2021 [PMID: 34647903 DOI: 10.1530/ERC-21-0152]

58 **Rodriguez-Freixinos V**, Chan D, Doherty M, Wasson K, Lscoe N, Raskin W, Hallet J, Myrehaug S, Law C, Thawer A. Avelumab in Unresectable/Metastatic, Progressive, Poorly Differentiated, Grade 3 Neuroendocrine Carcinomas (NECs). Proceedings of the 17th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease. 2020 Mar 11-13. Neuroendoccrinology: 217

59 **Uboha NV**, Milhem MM, Kovacs C, Amin A, Magley A, Purkayastha DD, Piha-Paul SA. Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies. *J Clin Oncol* 2019; **37**: 2553 [DOI: 10.1200/JCO.2019.37.15\_suppl.2553]

60 **Morse M**, Halperin DM, Uronis HE, Hsu DS, Hurwitz H, Bolch E, Warren D, Haley S, John L, Moyer A, Rushing CN, Niedzwiecki D. Phase Ib/II study of pembrolizumab with lanreotide depot for advanced, progressive gastroenteropancreatic neuroendocrine tumors (PLANET). *J Clin Oncol* 2021; **39**: 369 [DOI: 10.1200/JCO.2021.39.3\_suppl.369]

**Footnotes**

**Conflict-of-interest statement:** The authors have no conflict of interests to report.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author's Membership in Professional Societies:** Neuroendocrine Tumor Expert Committee, Chinese Society of Clinical Oncology; Colorectal Cancer Expert Committee, Chinese Society of Clinical Oncology.

**Peer-review started:** September 8, 2021

**First decision:** October 16, 2021

**Article in press:** November 30, 2021

**Specialty type:** Oncology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Ahmed M, Cho JH **S-Editor:** Yan JP **L-Editor:** Filipodia **P-Editor:** Yan JP

**Table 1 Clinical trials related to gastroenteropancreatic neuroendocrine tumors**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **ClinicalTrials.gov identifier** | **Intervention** | **Study phase** | **Trial name** | **Primary outcome** | **Estimated/actual enrollment, *n*** | **Estimated/actual date** | **Trial status** | **Medical condition related to advanced NENs** | **Reported assessable n of NENs** |
| NCT02054806[21] | Pembrolizumab | Ib | Phase Ib study of pembrolizumab (MK-3475) in subjects with select advanced solid tumors (MK-3475-028/KEYNOTE-028) | ORR | 477 | April 30, 2021 | Completed | pNETs: PD-L1 (+), well or moderately differentiated | 16 pNETs |
| NCT02628067[22] | Pembrolizumab | II | A clinical trial of pembrolizumab (MK-3475) evaluating predictive biomarkers in subjects with advanced solid tumors (KEYNOTE-158) | ORR | 1595 | June 18, 2026 | Recruiting | NETs: Well or moderately differentiated | 107 NETs: Lung, appendix, small intestine, colon, rectum, or pan origin |
| NCT02939651[23] | Pembrolizumab | II | A phase 2, open-label study of pembrolizumab monotherapy in patients with metastatic high grade neuroendocrine tumors | ORR | 21 | March 2020 | Completed | G3 NENs: Ki-67 > 20%, poorly or well-differentiated, failed for platinum based chemotherapy, excluding MCC, large/small cell NENs of lung/thymus origin | 29 G3 NENs: 19 NECs, 9 G3 NET, 14 Ki-67 ≤ 50%, 12 Ki-67 > 50%, 10 pan, 14 GI, 5 unknown origin |
| NCT03136055[24,48] | Part A: pembrolizumab alone; Part B: Pembrolizumab + chemotherapy | II | A pilot study of pembrolizumab-based therapy in previously treated high grade neuroendocrine carcinomas | ORR | 36 | May 31, 2023 | Active, not recruiting | EP-PDNECs: Failed for first-line systemic therapy, excluding MCC or well differentiated G3 NET | Part A: 13 EP-PDNECs; Part B: 22 EP-PDNEC |
| NCT03190213 | Pembrolizumab | II | Pembrolizumab for the treatment of recurrent high grade neuroendocrine carcinoma (Pembro NEC) | ORR (irRECIST) | 6 | March 11, 2019 | Terminated | G3 NENs: Failed for platinum-based regimen or temozolomide-based regimen. exluding lung origin | 6 G3 NENs |
| NCT02955069[25] | Spartalizumab | II | An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastrointestinal (GI), or thoracic origin or poorly-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), that have progressed on prior treatment | ORR | 116 | May 13, 2020 | Completed | NENs: Exclude G3 NETs and include G1/2 NET (non-functional, GEP or thoracic origin, failed to prior treatment) and GEP-NEC (progressed on or after one prior chemotherapy regimen) | 99 NETs: 30 thoracic, 32 GI-NET, 33 pNET; 21 GEP-NEC |
| NCT03167853[30] | Toripalimab | Ib | Phase Ib study of safety and efficacy of recombinant humanized anti-PD-1 monoclonal antibody for patients with advanced neuroendocrine tumors following failure of first-line | ORR | 40 | May 11, 2019 | Completed | NENs: Ki-67 ≥ 10%, nonfunctional NENs, well- or poorly-differentiated, failed for first line therapy | 40 NENs: 8 well-differentiated, 32 poorly-differentiated |
| NCT03352934[26] | Avelumab | II | A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab in patients with advanced, metastatic high grade neuroendocrine carcinomas NEC G3 (WHO 2010) progressive after chemotherapy (AveNEC) | DCR | 60 | January 2024 | Active, not recruiting | G3 NENs: after first-line chemotherapy, excluding MCC, SCLC | 29 G3 NENs: 16 NEC and 11 G3 NETs, 12 pan, 5 GI, 9 other origin) |
| NCT03278405[58] | Avelumab | IIa | A pilot study of avelumab in unresectable/metastatic, progressive, poorly differentiated grade 3 neuroendocrine carcinomas (NET001) | ORR | 10 | March 12, 2020 | Completed | NECs: Poorly-differentiated, GI or lung origin, have received 0-2 prior lines of systemic therapy, excluding MANEC | 10 NECs: 9  GI and 1 lung |
| NCT03278379[28] | Avelumab | II | A phase II study of avelumab in unresectable/metastatic, progressive grade 2-3 neuroendocrine tumors (NET-002) | ORR | 17 | September 20, 2021 | Active, not recruiting | G2-3 NETs: GEP or lung, received 0-2 prior lines of therapy (excluding SSAs), excluding G1 NET, NEC and MANEC | 17 G2-3 NETs (12 GEP, 5 lung) |
| NCT03147404 | Avelumab | II | Phase II study of avelumab in metastatic gastronetro-pancreatic (GEP) neuroendocrine carcinoma (NEC, WHO Grade 3) as second-line treatment after failing to etoposide + cisplatin: integration of genomic analysis to identify predictive molecular subtypes (MS100070-0177) | Best response | 14 | July 22, 2019 | Completed | G3 GEP-NECs: Second-line treatment after failing to etoposide + cisplatin | - |
| NCT03879057[39] | Toripalimab + surufatinib | I | Phase I trial evaluating the safety, tolerability, pharmacokinetics, and efficacy of surufatinib combined with JS001 in patients with advanced solid tumors | AEs, MTD | 24 | December 20, 2021 | Recruiting | NENs: G1-3 NET, NEC | 18 NENs:11 NECs,4 G2 NETs; 4 G3 NETs, 12 GI,4 pan, 1 lung |
| NCT04169672[40] | Toripalimab + surufatinib | II | A phase II, open-label, single-arm, multi-center study of the efficacy and safety of surufatinib combined with toripalimab in patients with advanced solid tumors | AEs, ORR | 200 | February 28, 2022 | Recruiting | NECs: Refractory to first-line chemotherapy | 20 NECs |
| NCT03475953 | Avelumab + regorafenib | I/II | A phase I/II study of regorafenib plus avelumab in solid tumors (REGOMUNE) | Phase I: Recommended dose of regorafenib; Phase II: ORR, PFS | 482 | May 2022 | Recruiting | G2/3 GEP-NETs | - |
| NCT03290079 | Pembrolizumab + lenvatinib | II | Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors | ORR | 35 | December 2023 | Recruiting | NETs: Well-differentiated, lung, thymus, small bowel or colon origin, including unknown primary, excluding pNENs and poorly differentiated NECs | - |
| NCT04579757 | Surufatinib + tislelizumab | Ib/II | An open-label phase Ib/II study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors | DLT, ORR | 120 | April 30, 2023 | Recruiting | G1/2 NETs: Thoracic or GEP origins, have progressed on at least one line of standard therapy | - |
| NCT04207463 | AK105 + anlotinib | II | A phase II, open, single-arm, multi-cohort, multicenter study of anlotinib and AK105 (anti-PD-1) injection in subjects with gastrointestinal tumors, urinary system tumors, neuroendocrine tumors | ORR | 150 | May 30, 2021 | Recruiting | G1/2 GEP-NETs | - |
| NCT03074513[41] | Atezolizumab + bevacizumab | II | A phase II, single-arm open-label study of the combination of atezolizumab and bevacizumab in rare solid tumors | ORR | 164 | March 31, 2021 | Active, not recruiting | G1/2 NETs: pNET cohort and epNET cohort containing typical or atypical carcinoid if originating in lung | 20 G1/2 pNETs, 20 G1/2 epNETs |
| NCT02923934[45] | Nivolumab + ipilimumab | II | A phase II clinical trial evaluating ipilimumab and nivolumab in combination for the treatment of rare gastrointestinal, neuro-endocrine and gynaecological cancers (CA209-538) | CBR | 120 | December 2023 | Active, not recruiting | NENs: G1-3 NETs, NECs, GEP or lung origin | 10 GEP-NENs: 7 pNENs (3 G3 pNETs, 2 pNECs, 2 G2 pNETs); 3 GI-NENs (1 gastro-oesophageal junction NEC, 1 colonic NECs, 1 G1 gastric NET) |
| NCT02834013[15,46] | Nivolumab + ipilimumab | II | A prospective, open-label, multicenter phase II basket clinical trial of ipilimumab plus nivolumab across multiple rare tumor cohorts (DART) | ORR | 818 | August 1, 2021 | Recruiting | SWOG 1609 cohort: Refractory epNENs. G3 NETs were included in G3 NECs. SWOG S1609 cohort: Dedicated cohort include G3 NENs | SWOG 1609 cohort: 32 epNENs (18 G3, 10 G2, 4 G1, 15 GI, 6 Lung). S1609 cohort: 19 G3 NENs (2 G3 NETs, 11 NEC, 6 unknown differentiation status) |
| NCT04969887 | Nivolumab + ipilimumab | II | Ipilimumab and nivolumab combination therapy in patients with selected immunotherapy sensitive advanced rare cancers (MOST-CIRCUIT) | CBR | 240 | December 2024 | Not yet recruiting | NECs and G3 NETs independent of primary site, excluding SCLC | - |
| NCT03591731 | Nivolumab alone or nivolumab + ipilimumab | II | A GCO trial exploring the efficacy and safety of nivolumab monotherapy or nivolumab plus ipilimumab in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (NIPINEC) | ORR | 180 | September 2023 | Recruiting | NECs: Poorly differentiated, refractory, pulmonary or GEP, excluding SCLC | - |
| NCT03095274[47] | Tremelimumab + durvalumab | II | A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with advanced neuroendocrine neoplasms of gastroenteropancreatic or lung origin (DUNE) (GETNE 1601) | Cohort 1-3: CBR at 9 m; Cohort 4: OS at 9 mo | 126 | July 2021 | Recruiting | G1/G2 NETs of GEP and lung, and G3 of GEP or unknown primary site (excluding lung primaries) after progression to standard therapies | 123 NENs (Cohort 1: 27 typical/atypical lung carcinoid; Cohort 2: 31 G1/2 GI-NENs; Cohort 3: 32 G1/2 pNENs; Cohort 4: 33 G3 NEN of GEP or unknown primary site) |
| NCT04079712 | Nivolumab + ipilimumab + cabozantinib | II | A phase 2 study of XL184 (Cabozantinib) in combination with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas | ORR | 30 | October 1, 2021 | Recruiting | NECs: All variations of poorly differentiated NECs (small cell, large cell and mixed cells) are eligible, excluding SCLC and MCC. Failure of only one line of prior systemic cancer treatment | - |
| NCT03728361[49] | Nivolumab + temozolomide | II | A phase II, multi-cohort trial of combination nivolumab and temozolomide in recurrent/refractory small-cell lung cancer and advanced neuroendocrine tumors | ORR | 55 | December 31, 2021 | Active, not recruiting | NENs: Any grade or primary site | 12 NENs: 1 G1, 8 G2, 3 G3 |
| NCT03980925 | Nivolumab + platinum-doublet chemotherapy | II | A phase II study of platinum-doublet chemotherapy in combination with nivolumab as first-line treatment in subjects with unresectable, locally advanced or metastatic G3 neuroendocrine neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or of unknown (UK) origin (GETNE-T1913) | OS at 12 mo | 38 | December 2022 | Recruiting | G3 NENs: GEP or unknown primary site | - |
| NCT03365791[59] | Spartalizumab + LAG525 | II | Modular phase 2 study to link combination immune-therapy to patients with advanced solid and hematologic malignancies. Module 9: PDR001 plus LAG525 for patients with advanced solid and hematologic malignancies | CBR at 24 wk | 76 | September 17, 2020 | Completed | NETs: Well-differentiated, relapsed and/or refractory to available standard of care therapies | 7 NETs |
| NCT03043664[60] | Pembrolizumab + lanreotide depot | Ib/II | Phase Ib/II study of pembrolizumab with lanreotide depot for gastroenteropancreatic neuroendocrine tumors (PLANET) | ORR | 22 | September 1, 2021 | Active, not recruiting | G1-2 GEP-NETs: Had progressed on a prior SSA | 22 G1/2 GEP-NETs (14 GI, 8 pan) |
| NCT04525638 | Nivolumab + 177Lu-DOTATATE | II | A phase II single arm trial evaluating the preliminary efficacy of the combination of 177Lu-DOTATATE and nivolumab in grade 3 well-differentiated neuroendocrine tumours (NET) or poorly differentiated neuroendocrine carcinomas (NEC) | ORR | 30 | September 30, 2024 | Recruiting | G3 NENs: GEP or unknown primary site, well-differentiated or poorly-differentiated. | - |
| NCT04701307 | Dostarlimab + niraparib | II | Niraparib (PARP Inhibitor) plus dostarlimab (Anti-PD1) for small cell lung cancer (SCLC) and other high-grade neuroendocrine carcinomas (NEC) | 6 mo PFS, 3 mo ORR | 48 | May 30, 2025 | Recruiting | G3 NECs: SCLC (Cohort 1) and other G3 NECs (Cohort 2), had at least one prior line of systemic therapy, excluding prostate origin | - |
| NCT03457948 | Group I: Pembrolizumab + 177Lu DOTATATE; Group II: Pembrolizumab + TAE; Group III: Pembrolizumab + 90Yttrium- Microsphere Radioembolization | II | A pilot study of pembrolizumab and liver-directed therapy or peptide receptor radionuclide therapy for patients with well-differentiated neuroendocrine tumors and symptomatic and/or progressive metastases | ORR | 32 | March 31, 2024 | Recruiting | G1-3 NETs: Well-differentiated, any primary site and unknown primary site, have liver metastases | - |
| NCT03879694 | SVN53-67/M57-KLH peptide vaccine (SurVaxM) +Octreotide | I | A phase I study of safety and immunogenicity of Survivin Long Peptide Vaccine (SurVaxM) in patients with metastatic neuroendocrine tumors (NETs) | AEs | 10 | June 13, 2024 | Recruiting | NETs: GEP or lung origin, positive for survivin | - |
| NCT04166006 | Dendritic cells loaded with autologous tumour (DC vaccine) + IL-2 | II | A phase II study on adjuvant vaccination with dendritic cells loaded with autologous tumor homogenate in resected stage iv rare cancers: Head & neck (H & N), neuroendocrine tumors (NET) and soft tissue sarcoma (STS) | Treatment-Emergent AEs | 51 | December 2026 | Recruiting | NET: Stage IV | - |

AE: Adverse event; CBR: Clinical benefit rate; DCR: Disease control rate; DLT: Dose-limiting toxicity; EP-PDNECs: Extrapulmonary poorly differentiated neuroendocrine carcinomas; ep: Extra-pancreatic; G1, 2, 3: Grade 1, 2, 3; GEP: Gastroenteropancreatic; GI: Gastrointestinal; irRECIST: Immune-related Response Evaluation Criteria in Solid Tumors; MANEC: Mixed adenoneuroendocrine carcinomas; MCC: Merkel cell carcinoma; MTD: Maximum tolerated dose; NECs: Neuroendocrine carcinomas; NENs: Neuroendocrine neoplasms; NETs: Neuroendocrine tumors; ORR: Objective response rate; OS: Overall survival; p: Pancreatic; pan: Pancreas origin; PD-1: Programmed cell death protein 1; PD-L1: Programmed death-ligand 1; PFS: Progression-free survival; SCLC: Small cell lung cancer; WHO: World Health Organization.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**